Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SEER
stocks logo

SEER

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.60M
+15%
-0.320
-13.51%
4.50M
+7.02%
-0.350
+2.94%
5.00M
+23.43%
-0.340
+3.03%
Estimates Revision
The market is revising Downward the revenue expectations for Seer, Inc. (SEER) for FY2025, with the revenue forecasts being adjusted by -2.86% over the past three months. During the same period, the stock price has changed by -8.57%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.86%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-8.57%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Seer Inc (SEER.O) is -1.45, compared to its 5-year average forward P/E of -9.37. For a more detailed relative valuation and DCF analysis to assess Seer Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.37
Current PE
-1.45
Overvalued PE
4.19
Undervalued PE
-22.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.64
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.34
Undervalued EV/EBITDA
-22.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
110.14
Current PS
0.00
Overvalued PS
368.85
Undervalued PS
-148.57
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

SEER News & Events

Events Timeline

(ET)
2025-12-01
07:19:00
Seer Publishes Large Genome-Wide Study Confirming Importance of Mass Spectrometry Validation
select
2025-11-07 (ET)
2025-11-07
07:11:18
Seer Unveils Latest Data at the 2025 HUPO World Congress
select
2025-09-02 (ET)
2025-09-02
07:06:24
Seer names Isaac Ro to its board of directors
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-01Globenewswire
Seer Publishes Large GWAS Study Validating Mass Spectrometry's Role in Proteomics
  • Significant Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a GWAS involving approximately 1,600 blood samples, showcasing its robust capabilities in protein research and advancing precision medicine.
  • Importance of Validation: The study reveals that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby reducing technical noise in research.
  • New Discoveries: Among 364 genetic variants associated with protein abundance, 102 were validated in an independent cohort, with 35 being newly reported, thus expanding the knowledge base of genetic regulation of proteins and deepening biomedical research.
  • Clinical Impact: By providing more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, ensuring that future therapies are built on real biology, which increases the likelihood of success in clinical applications.
[object Object]
Preview
3.5
12-01Newsfilter
Seer Publishes Large GWAS Validating Mass Spectrometry's Role in Proteomics
  • Significant Research Findings: Seer's Proteograph platform detected 5,753 proteins and quantified 1,980 in a genome-wide association study involving approximately 1,600 blood samples, showcasing its robust capabilities in protein abundance research and reinforcing the company's leadership in precision medicine.
  • Importance of Validation: The study revealed that about one-third of protein-gene associations reported without mass spectrometry validation do not replicate, underscoring the critical role of mass spectrometry in ensuring the reliability of drug targets and clinical biomarkers, thereby enhancing Seer's market competitiveness.
  • New Discovery Potential: Among 364 protein quantitative trait loci (pQTLs), 102 were validated in an independent cohort, with 35 being newly reported, which not only expands the knowledge base of protein genetic regulation but also provides new directions for future drug development.
  • Clinical Application Prospects: By offering more reliable protein measurements, Seer's research lays the groundwork for drug discovery and biomarker development, reducing risks associated with technical noise and increasing the likelihood of success in clinical research, thus advancing translational medicine.
[object Object]
Preview
3.5
11-07Newsfilter
Seer and Partners Present Extensive New Findings Showcasing the Translational Potential of Deep Proteomics at HUPO 2025

  • Seer, Inc. Announcement: Seer, Inc. presented new data at the HUPO World Congress 2025, showcasing how its Proteograph Product Suite is advancing research in cardiovascular, oncology, and aging biology by translating complex biological signatures into actionable insights.

  • Impact of Proteomics: The studies highlighted at the congress demonstrate the scalability and relevance of proteomics, moving from specialized studies to population-scale discoveries that link molecular insights to clinical applications.

  • Seer Breakfast Symposium: The symposium featured discussions on deep proteomics in cardiac dysfunction and aging, with presentations revealing novel biomarkers and disease mechanisms, emphasizing the technology's role in accelerating translational research.

  • Comprehensive Scientific Presentations: Over a dozen scientific presentations and posters were showcased, illustrating the diverse applications of Seer's technology in biomarker discovery and disease insights across various research areas.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Seer Inc (SEER) stock price today?

The current price of SEER is 1.92 USD — it has increased 1.59 % in the last trading day.

arrow icon

What is Seer Inc (SEER)'s business?

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.

arrow icon

What is the price predicton of SEER Stock?

Wall Street analysts forecast SEER stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEER is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Seer Inc (SEER)'s revenue for the last quarter?

Seer Inc revenue for the last quarter amounts to 4.12M USD, increased 2.21 % YoY.

arrow icon

What is Seer Inc (SEER)'s earnings per share (EPS) for the last quarter?

Seer Inc. EPS for the last quarter amounts to -0.32 USD, decreased -8.57 % YoY.

arrow icon

What changes have occurred in the market's expectations for Seer Inc (SEER)'s fundamentals?

The market is revising Downward the revenue expectations for Seer, Inc. (SEER) for FY2025, with the revenue forecasts being adjusted by -2.86% over the past three months. During the same period, the stock price has changed by -8.57%.
arrow icon

How many employees does Seer Inc (SEER). have?

Seer Inc (SEER) has 134 emplpoyees as of December 05 2025.

arrow icon

What is Seer Inc (SEER) market cap?

Today SEER has the market capitalization of 107.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free